12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry

PURPOSE: To compare 12‐month treatment outcomes of eyes receiving aflibercept or ranibizumab for macular oedema secondary to central retinal vein occlusion (CRVO) in routine clinical practice. METHODS: 296 treatment‐naïve eyes receiving either aflibercept (171 eyes, 2 mg) or ranibizumab (125 eyes, 0...

Descripción completa

Detalles Bibliográficos
Autores principales: Niedzwiecki, Mateusz, Hunt, Adrian, Nguyen, Vuong, Mehta, Hemal, Creuzot‐Garcher, Catherine, Gabrielle, Pierre‐Henry, Guillemin, Martin, Fraser‐Bell, Samantha, Arnold, Jennifer, McAllister, Ian L., Gillies, Mark, Barthelmes, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292733/
https://www.ncbi.nlm.nih.gov/pubmed/34519167
http://dx.doi.org/10.1111/aos.15014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292733/
https://www.ncbi.nlm.nih.gov/pubmed/34519167
http://dx.doi.org/10.1111/aos.15014

Ejemplares similares